Medicus Pharma (NASDAQ:MDCX – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08), Zacks reports.
Medicus Pharma Price Performance
Shares of NASDAQ MDCX opened at $0.35 on Friday. The stock’s 50-day moving average is $0.37 and its two-hundred day moving average is $0.54. Medicus Pharma has a 1-year low of $0.25 and a 1-year high of $3.05. The company has a market cap of $20.06 million, a price-to-earnings ratio of -0.14 and a beta of 0.11.
Analysts Set New Price Targets
MDCX has been the topic of a number of analyst reports. Alliance Global Partners began coverage on shares of Medicus Pharma in a research note on Tuesday, July 28th. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a report on Wednesday, July 8th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Medicus Pharma in a research report on Monday, April 20th. Finally, Roth Capital assumed coverage on Medicus Pharma in a report on Tuesday, April 21st. They issued a “buy” rating on the stock. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.00.
Institutional Investors Weigh In On Medicus Pharma
A number of hedge funds have recently added to or reduced their stakes in MDCX. Armistice Capital LLC acquired a new stake in shares of Medicus Pharma in the 4th quarter valued at approximately $2,771,000. Jane Street Group LLC acquired a new stake in shares of Medicus Pharma during the 4th quarter worth $92,000. HRT Financial LP purchased a new position in shares of Medicus Pharma in the 4th quarter worth about $42,000. Wilmington Savings Fund Society FSB lifted its position in Medicus Pharma by 100.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock valued at $78,000 after buying an additional 25,622 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after purchasing an additional 17,611 shares during the period.
About Medicus Pharma
Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.
Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.
Featured Stories
- Five stocks we like better than Medicus Pharma
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
